|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:ATCCode
|
N03AG01
|
|
gptkbp:CASNumber
|
99-66-1
|
|
gptkbp:chemicalFormula
|
C8H16O2
|
|
gptkbp:contains_functional_group
|
gptkb:carboxylic_acid
|
|
gptkbp:contraindication
|
gptkb:liver_disease
gptkb:urea_cycle_disorders
pregnancy
|
|
gptkbp:discoveredBy
|
gptkb:Pierre_Eymard
|
|
gptkbp:discoveredIn
|
1962
|
|
gptkbp:drugClass
|
anticonvulsant
mood stabilizer
|
|
gptkbp:eliminationHalfLife
|
9–16 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
2-propylpentanoic acid
|
|
gptkbp:KEGGID
|
D00425
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:meltingPoint
|
121 °C
|
|
gptkbp:MeSH_ID
|
D014635
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
144.211 g/mol
|
|
gptkbp:otherName
|
gptkb:valproic_acid
|
|
gptkbp:PubChem_CID
|
3121
CHEMBL467
3009
|
|
gptkbp:riskFactor
|
gptkb:encephalopathy
gptkb:polycystic_ovary_syndrome
birth defects
pancreatitis
weight gain
hepatotoxicity
thrombocytopenia
hyperammonemia
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
nausea
tremor
hair loss
weight gain
drowsiness
liver toxicity
teratogenicity
|
|
gptkbp:solubility
|
slightly soluble
|
|
gptkbp:UNII
|
614OI1Z5WI
|
|
gptkbp:usedFor
|
bipolar disorder
epilepsy
migraine prevention
|
|
gptkbp:bfsParent
|
gptkb:valproic_acid
|
|
gptkbp:bfsLayer
|
6
|